Press Release

Champions Biotechnology Moves to Baltimore's Science + Technology Park at Johns Hopkins

For immediate release: February 19, 2009

Baltimore, MD - The Forest City-New East Baltimore Partnership (FC-NEBP) announces that effective February 2, Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR) has taken space at 855 North Wolfe Street at the Science + Technology Park at Johns Hopkins, occupying laboratory space on the sixth floor of The John G. Rangos, Sr. building. Colliers Pinkard/ROC Realty represented FC-NEBP and Champions in the transaction.

Champions relocated its East Coast operations from Arlington VA, to Baltimore to be in close proximity to Johns Hopkins University (JHU), home to the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and to some of the world's top researchers in the School of Medicine. Champions is engaged in the development of advanced preclinical platforms to enhance and accelerate the value of oncology drugs. It also offers physicians tumor-specific data for personalized patient care, permitting the evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery. Dr. David Sidransky, M.D., professor of oncology at the Johns Hopkins School of Medicine, widely recognized for his work in the early detection of cancer, is the Chairman of Champions' Board of Directors.

"We are pleased to be moving into this new space, a move made possible in part by Maryland Governor Martin O'Malley's Bio 2020 initiative," said Doug Burkett, PhD, President of Champions Biotechnology, Inc. "Especially given Dr. Sidransky's long and renowned affiliation with Johns Hopkins, we are excited to further solidify our ties with both the university and the great city of Baltimore."

Champions moved into space within 855 North Wolfe Street specifically designed to provide emerging companies with fully-equipped, occupant-ready suites ranging in size from 1,100 to 1,400 square feet, with fee-based access to outstanding core facilities at Johns Hopkins. Champions was able to get operations up and running within 48 hours of signing their lease.

"We are pleased that JHU and the Maryland Department of Business and Economic Development have partnered with FC-NEBP to make ready-to-go lab space like this affordable," said Scott Levitan, Sr. Vice President, Forest City Science + Technology Group. "Champions had many options in the market, however, the cost, amenities and access to the JHU research equipment our Park offers demonstrates that we are value-competitive. FC-NEBP listens to prospective tenants like Champions and develops lease terms that meet their needs."

Champions joins a growing cluster of institutional and commercial tenants at 855 North Wolfe Street who recognize the benefits of being located in a top tier science facility in such close proximity to the Johns Hopkins Medical Institutions and the opportunities for scientific collaboration and access to Johns Hopkins' core facilities at the East Baltimore campus. Johns Hopkins is committed to the success of companies in the Park and their array of special services and opportunities for peer collaboration, both formal and informal; foster the emergence of this new, commercially-based scientific community.

"The investments we make in Maryland's biotech industry today are building a solid foundation for our State's future," said Christian S. Johansson, Acting Secretary of the Maryland Department of Business and Economic Development. "Governor O'Malley's visionary Bio 2020 initiative is a key factor in why we are continuing to see an influx of cutting-edge companies like Champions choose Maryland as the ideal place to grow and expand."

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.

The New East Side

The Science + Technology Park at Johns Hopkins is just one component of the transformation of the East Baltimore community being overseen by East Baltimore Development Inc., (EBDI). The New East Side will provide residential units for new and returning residents in mixed-income housing, as well as offer life science, office and retail space. EBDI (www.ebdi.org) coordinates access to customized technical skills training programs that enable more of Baltimore's workforce to meet the requirements of companies locating in the Park. A new K-8 community school and open spaces are also planned within the EBDI footprint.

Collaborators working to rebuild the community and create new opportunities within East Baltimore include the State of Maryland, the City of Baltimore, East Baltimore Development Inc., the Annie E. Casey Foundation, the Johns Hopkins Institutions, The Henry and Jeanette Weinberg Foundation, the Goldseker Foundation, Forest City-New East Baltimore Partnership, and its subdevelopers.

About The Park & The Developers
The Science + Technology Park at Johns Hopkins is part of an ambitious, mixed-use development program in an area of East Baltimore immediately north of the Johns Hopkins Medical Institutions. The first phase of the development includes the 1.1-million-square-foot Science + Technology Park, over 850 housing units for mixed-income buyers and renters, and a variety of retail services, all of which will generate new job opportunities. The Partnership consists of the Forest City Science + Technology Group and Presidential Partners, LLC (www.presidentialpartenrsllc.com), a minority-business consortium of Baltimore-based, award-winning developers, specializing in mixed-use projects including, Banks Contracting, Lambda Development, Legacy Harrison Enterprises, and The Wilkinson Group. Presidential Partners has earned recognition for top-notch strategic planning, innovative collaboration, and an enviable ability to spot and spark urban revitalization.

Forest City Science + Technology Group (www.forestcityscience.net) operates a portfolio of more than two million square feet of life science/technology office space, with more than eight million square feet in the planning or development stages. Its properties are in major markets including Boston, Baltimore, Philadelphia, Chicago and Denver.

Forest City Science + Technology Group is a division of Forest City Enterprises, Inc. (NYSE: FCEA) (NYSE: FCEB), a $10.9 billion NYSE-listed national real estate company. The Company is principally engaged in the ownership, development, management and acquisition of commercial and residential real estate and land throughout the United States.

Safe Harbor Language
Statements made in this news release that state Forest City's or management's intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. The Company's actual results could differ materially from those expressed or implied in such forward-looking statements due to various risks, uncertainties and other factors. Real estate development risks and factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the inability to secure sufficient financing on favorable terms, construction risks, increases in commodity costs, the inability to obtain required governmental permits and authorizations, the inability to secure tenants or anchors for the project, the withdrawal of a prospective anchor or project partner, opposition from third parties, competition in the target market, economic conditions in the target market, the adverse impact of environmental matters, softening of the housing market, and other risk factors as disclosed from time to time in the Company's SEC filings, including but not limited to, the Company's annual and quarterly reports.